Table 2.

Studies reporting negative prognostic value of HER2 protein expression or gene amplification in urothelial carcinoma

Author/reference	Correlative outcome/HER2 marker	Patients/Cases
Chakravarti et al [61]	lower complete response rate to chemoradiation / protein expression	73
Lönn et al [63]	aneuploidy, higher grade, shorter overall survival / protein expression	91
Lipponen et al [62]	higher stage and grade, shorter overall survival / gene amplification	178
Masliukova et al [68]	shorter relapse-free survival/ protein expression / protein expression	63
Kolla et al [69]	higher stage and grade, positive lymph node status, shorter disease-free and disease-related survival / protein expression	90
Krüger et al [70]	higher grade, shorter disease-free and disease-related survival / protein expression	138
Tsai et al [71]	site (bladder vs upper urinary tract), shorter progression-free and disease-related survival / protein expression	114
Skagias et al [72]	higher stage, grade, shorter disease-specific and overall survival / protein expression	80
Bolenz et al [73]	lymph nodes (vs primary site), lymphovascular invasion, higher recurrence risk, shorter disease-specific survival / protein expression	198
Alexa et al [74]	higher grade/ protein expression	59